8th EUROPEAN SCHOOL OF DERMATO-ONCOLOGY
UPDATE ON CUTANEOUS ONCOLOGY (ESDO)
JANUARY 16th-18th, 2020
ABBA HOTEL BERLIN, GERMANY
European Association of Dermato-Oncology (EADO)

The EADO is a non-profit organization funded in 1999 to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. EADO has organized many successful meetings and the upcoming ones are visible on the website (www.eado.org).

The EADO initiates for the eighth time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of locoregional disease and distant metastatic disease.

Target Audience

This 2,5-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course.

Educational Objectives

The principal aim of the course is to provide a comprehensive and detailed understanding of the decision-making process for the management of all types and stages of skin cancer. This will include diagnosis and primary treatment, management of locoregional disease and distant metastatic disease, and adjuvant treatment. This is particularly relevant given the rapid progress in our understanding of melanoma and non-melanoma skin cancer, and the development of new treatments. In particular delegates will acquire the following knowledge:

1. Strategies for diagnosis of melanoma, Merkel cell and non-melanoma skin cancer including dermoscopy and confocal laser microscopy.
2. The indications, risks and benefits and strategies for mole screening.
3. Diagnosis of skin cancer: how to break bad news.
5. The present AJCC staging systems and how to stage melanoma, Merkel cell and cutaneous squamous cell carcinoma, and other non-melanoma skin cancers.
6. The value of imaging and biomarkers for the detection of metastases and disease staging.
8. New systemic treatments for stage IV melanoma: targeted agents and immunotherapeutics.
10. New systemic treatments for advanced Merkel cell and squamous cell carcinoma.
11. The characteristics of mucosal and uveal melanomas and their treatment options.
12. Options for topical treatment of epithelial skin cancers.
13. The current classification of cutaneous lymphoma, staging and treatment options for different subtypes of cutaneous lymphoma.
15. The indications and strategies for supportive treatments including best supportive care.

**Course Organization**

The course consists of plenary sessions and interactive outbreak sessions. Plenary sessions will comprise clear structured and up-to-date presentations followed by audience discussion. Voting devices will be used to respond to multiple choice questions. These questions may precede the presentation of the structured knowledge or may be presented at the end in order to test the level of knowledge the audience has gained.

The main part of the course consists of 8 interactive sessions, each with no more than 30 attendees. Every participant takes part in each of these sessions which mainly comprise case-based discussion. These will be used to illustrate treatment pathways, how risk and benefit are assessed, and how management decisions are made.

We look forward to welcoming you in Berlin in January 2020!

Ana-Maria Forsea, MD
Claus Garbe, MD
Axel Hauschild, MD
Judit Oláh, MD

*Course Directors*
# Program Overview

A commercial exhibition will be held on all days close to the meeting rooms.

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
</tr>
</tbody>
</table>

**Thursday, January 16th, 2020**

- **Group I**
- **Group II**
- **Group III**
- **Group IV**

**Friday, January 17th, 2020**

**Non-Melanoma Skin Cancer Day**

- **Course A+E**: Valencia
- **Course B+F**: Pamplona
- **Course C+G**: Santander
- **Course D+H**: Burgos
- **Course E**: Salamanca

All meeting rooms are located on the ground floor.

**Saturday, January 18th, 2020**

- **Group I**
- **Group II**
- **Group III**
- **Group IV**

---

**PLENARY SESSION 2**

- **A. Stratigos**
- **D. Schadendorf**
- **V. del Marmol**
- **C. Garbe**

**PLENARY SESSION 4**

- **L. K. Seculovic**
- **J. J. Grob**
- **J. OIan**
- **R. Vieira**
- **Ch. Gebhardt**

---

**PLENARY SESSION 4**

- **L. K. Seculovic**
- **J. J. Grob**
- **J. OIan**
- **R. Vieira**
- **Ch. Gebhardt**

---

**PLENARY SESSION 4**

- **L. K. Seculovic**
- **J. J. Grob**
- **J. OIan**
- **R. Vieira**
- **Ch. Gebhardt**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45-14:00</td>
<td><strong>Welcome and course introduction</strong></td>
<td></td>
<td>Claus Garbe, Tuebingen, Germany</td>
</tr>
<tr>
<td><strong>PLENARY SESSION 1: What is new in diagnostics and treatment?</strong></td>
<td>Chairpersons: Iris Zalaudek and Joseph Malvehy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00-14:15</td>
<td><strong>LECTURE 1:</strong> Dermoscopy of difficult lesions – beyond ABCD</td>
<td>Valencia</td>
<td>Iris Zalaudek, Trieste, Italy</td>
</tr>
<tr>
<td>14:20-14:35</td>
<td><strong>LECTURE 2:</strong> Computer dermoscopy: a must?</td>
<td>Valencia</td>
<td>Aimilios Lallas, Thessaloniki, Greece</td>
</tr>
<tr>
<td>14:40-14:55</td>
<td><strong>LECTURE 3:</strong> Update on imaging tools in skin cancers</td>
<td>Valencia</td>
<td>Josep Malvehy, Barcelona, Spain</td>
</tr>
<tr>
<td>15:00-15:15</td>
<td><strong>LECTURE 4:</strong> The neoadjuvant approach in skin cancer</td>
<td>Valencia</td>
<td>Christoph Höller, Vienna, Austria</td>
</tr>
<tr>
<td>15:15-15:30</td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30-16:00</td>
<td><strong>Coffee Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>16:00-17:00</strong></td>
<td><strong>COURSE A:</strong> Clinical trials fundamentals – understanding trial design, data analysis, result interpretation and ethical issues</td>
<td>Pamplona</td>
<td>Jean Jacques Grob, Marseille, France</td>
</tr>
<tr>
<td><strong>16:00-17:00</strong></td>
<td><strong>COURSE B:</strong> How to organize a skin cancer center?</td>
<td>Santander</td>
<td>Celeste Lebbé, Paris, France</td>
</tr>
<tr>
<td><strong>16:00-17:00</strong></td>
<td><strong>COURSE C:</strong> Management of melanoma patients stages I-III</td>
<td>Burgos</td>
<td>Claus Garbe, Tuebingen, Germany</td>
</tr>
<tr>
<td><strong>16:00-17:00</strong></td>
<td><strong>COURSE D:</strong> Targeted therapy of melanoma, SCC, BCC and DFSP</td>
<td>Salamanca</td>
<td>Olivier Michielin, Lausanne, Switzerland</td>
</tr>
</tbody>
</table>
Friday, January 17th, 2020
Non-Melanoma Skin Cancer Day

PLENARY SESSION 2: Controversies in Dermatooncology
Chairpersons: Jean Jacques Grob and Alexander Stratigos

08:00-08:15 LECTURE 5: Sunscreens prevent skin cancer: Yes
Veronique del Marmol, Brussels, Belgium

08:15-08:30 LECTURE 6: Sunscreens prevent skin cancer: No
Claus Garbe, Tuebingen, Germany

08:30-08:45 Discussion

08:45-09:00 LECTURE 7: Skin cancer screening saves lifess: Yes
Alexander Stratigos, Athens, Greece

09:00-09:15 LECTURE 8: Skin cancer screening saves lifess: No
Dirk Schadendorf, Essen, Germany

09:15-09:30 Discussion

09:30-10:00 Coffee Break
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-11:00</td>
<td><strong>COURSE E</strong>: Principals of follow-up in skin cancer patients</td>
<td>Pamplona</td>
<td>Ana-Maria Forsea, Bucharest, Romania</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td><strong>COURSE F</strong>: Cutaneous lymphomas: diagnosis and management</td>
<td>Santander</td>
<td>Michael Weichenthal, Kiel, Germany</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td><strong>COURSE G</strong>: Surgical pearls in the treatment of keratinocyte skin cancer</td>
<td>Burgos</td>
<td>Roland Kaufmann, Frankfurt, Germany</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td><strong>COURSE H</strong>: Immune checkpoint inhibition for melanoma, MCC, SCC and BCC</td>
<td>Salamanca</td>
<td>Axel Hauschild, Kiel, Germany</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-12:30</td>
<td><strong>COURSE F</strong>: Cutaneous lymphomas: diagnosis and management</td>
<td>Santander</td>
<td>Michael Weichenthal, Kiel, Germany</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td><strong>COURSE G</strong>: Surgical pearls in the treatment of keratinocyte skin cancer</td>
<td>Burgos</td>
<td>Roland Kaufmann, Frankfurt, Germany</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td><strong>COURSE H</strong>: Immune checkpoint inhibition for melanoma, MCC, SCC and BCC</td>
<td>Salamanca</td>
<td>Axel Hauschild, Kiel, Germany</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td><strong>COURSE E</strong>: Principals of follow-up in skin cancer patients</td>
<td>Pamplona</td>
<td>Ana-Maria Forsea, Bucharest, Romania</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PLENARY SESSION 3</strong>: New challenges in skin cancer treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Holger Hänßle and Ketty Peris</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00-13:30</td>
<td><strong>LECTURE 9</strong>: Artificial intelligence in skin cancer diagnosis</td>
<td>Valencia</td>
<td>Holger Hänßle, Heidelberg, Germany</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td><strong>LECTURE 10</strong>: What is new for actinic keratosis?</td>
<td>Valencia</td>
<td>Ketty Peris, Rome, Italy</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td><strong>Non-Melanoma skin cancer cases – interactive presentation to the tumor board</strong></td>
<td>Valencia</td>
<td>Ana-Maria Forsea, Petr Arenberger, David Moreno</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Details</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30–16:30</td>
<td>COURSE G: <strong>Surgical pearls in the treatment</strong> of keratinocyte skin cancer</td>
<td>Roland Kaufmann, Frankfurt, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Group I</strong> Burgos</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30–16:30</td>
<td>COURSE H: <strong>Immune checkpoint inhibition for melanoma,</strong> MCC, SCC and BCC</td>
<td>Axel Hauschild, Kiel, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Group II</strong> Salamanca</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30–16:30</td>
<td>COURSE E: <strong>Principals of follow-up in skin cancer patients</strong></td>
<td>Ana-Maria Forsea, Bucharest, Romania</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Group III</strong> Pamplona</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30–16:30</td>
<td>COURSE F: <strong>Cutaneous lymphomas: diagnosis and management</strong></td>
<td>Michael Weichenthal, Kiel, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Group IV</strong> Santander</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30–17:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00–18:00</td>
<td>COURSE H: <strong>Immune checkpoint inhibition for melanoma,</strong> MCC, SCC and BCC</td>
<td>Axel Hauschild, Kiel, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Group I</strong> Salamanca</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00–18:00</td>
<td>COURSE E: <strong>Principals of follow-up in skin cancer patients</strong></td>
<td>Ana-Maria Forsea, Bucharest, Romania</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Group II</strong> Pamplona</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00–18:00</td>
<td>COURSE F: <strong>Cutaneous lymphomas: diagnosis and management</strong></td>
<td>Michael Weichenthal, Kiel, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Group III</strong> Pamplona</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00–18:00</td>
<td>COURSE G: <strong>Surgical pearls in the treatment</strong> of keratinocyte skin cancer</td>
<td>Roland Kaufmann, Frankfurt, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Group IV</strong> Burgos</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Saturday, January 18th, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Course</th>
<th>Location</th>
</tr>
</thead>
</table>
| 08:30-09:30   | **COURSE C:** Management of melanoma patients stages I-III  
                Claus Garbe, Tuebingen, Germany  
                | Group IV Santander                          |            |
| 08:30-09:30   | **COURSE D:** Targeted therapy of melanoma, SCC, BCC and DFSP  
                Olivier Michielin, Lausanne, Switzerland  
                | Group II Salamanca                          |            |
| 08:30-09:30   | **COURSE A:** Clinical trials fundamentals - understanding trial  
                design, data analysis, result interpretation and ethical issues  
                Jean Jacques Grob, Marseille, France  
                | Group III Pamplona                          |            |
| 08:30-09:30   | **COURSE B:** How to organize a skin cancer center?  
                Celeste Lebbé, Paris, France  
                | Group IV Santander                          |            |
| 09:30-10:00   | Coffee Break                                |            |
| 10:00-11:00   | **COURSE D:** Targeted therapy of melanoma, SCC, BCC and DFSP  
                Olivier Michielin, Lausanne, Switzerland  
                | Group I Salamanca                           |            |
| 10:00-11:00   | **COURSE A:** Clinical trials fundamentals - understanding trial  
                design, data analysis, result interpretation and ethical issues  
                Jean Jacques Grob, Marseille, France  
                | Group II Pamplona                           |            |
| 10:00-11:00   | **COURSE B:** How to organize a skin cancer center?  
                Celeste Lebbé, Paris, France  
                | Group III Pamplona                          |            |
| 10:00-11:00   | **COURSE C:** Management of melanoma patients stages I-III  
                Claus Garbe, Tuebingen, Germany  
                | Group IV Santander                          |            |
| 11:00-11:30   | Coffee Break                                |            |
|               | **PLENARY SESSION 4:** Melanoma diagnostics and follow-up  
                Chairpersons: Ketty Peris  
                |            |            |
| 11:30-12:00   | LECTURE 11: Targeted therapies: management of adverse events  
                Lidija Kandolf Sekulovic, Belgrade, Serbia  
                | Valencia                                     |            |
| 12:00-12:30   | LECTURE 12: Immune checkpoint inhibition:  
                management of adverse events  
                Christoffer Gebhardt, Hamburg, Germany  
                | Valencia                                     |            |
| 12:30-13:30   | Melanoma cases - interactive presentation to the tumor board  
                Judit Oláh, Lidija Kandolf, Ricardo Vieira  
                | Valencia                                     |            |
| 14:00-16:00   | European Examination Dermato-Oncology 2020    | Salamanca  |
Course Faculty

A

Petr Arenberger, MD
Professor of Dermatology, Director
Department of Dermatology
Charles University
3rd School of Medicine
Srobarova 50
CZ-100 34 Prague, Czech Republic
Phone: +420-26716-3000
Email: avemedica@email.cz

D

Veronique Del Marmol, MD
Department of Clinical Chemistry
Erasme Hospital - ULB
Route de Lennik 808
1070 Brussels, Belgium

F

Ana-Maria Forsea, MD
Associate Professor for Dermatology
Department of Dermatology
Carol Davila University of Medicine and Pharmacy Bucharest
Bulevardul Eroii Sanitarii 8
050474 Bucharest, Romania
Phone: +40-21-3180462
Email: aforsea@yahoo.com

G

Claus Garbe, MD
Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
72076 Tuebingen, Germany
Phone: +49-7071-2987110
Email: claus.garbe@med.uni-tuebingen.de

Christoffer Gebhardt, MD
Skin Cancer Center
University Hospital Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg, Germany
Phone: +49-40-741057626
Email: ch.gebhardt@uke.de

Jean Jacques Grob, MD
Professor of Dermatology
Service de Dermatology and Cancer Research
Hôpital de la Timone
264 Rue St. Pierre
13005 Marseille, France
Phone: +33-491-388591
Email: jean-jacques.grob@ap-hm.fr

H

Holger Hänßle, MD
Heidelberg University Hospital
Im Neuenheimer Feld 400
69120 Heidelberg, Germany
Axel Hauschild, MD  
Professor of Dermatology  
Department of Dermatology  
University of Kiel  
Rosalind-Franklin-Str. 7  
24105 Kiel, Germany  
Phone: +49-431-50021131  
Email: ahauschild@dermatology.uni-kiel.de

Christoph Höller, MD  
Professor of Dermatology  
Department of Dermatology  
Medical University of Vienna  
Waehringer Guertel 18-20  
1090 Vienna, Austria  
Phone: +43-1-404004786  
Email: christoph.hoeller@meduniwien.ac.at

L

Aimilios Lallas, MD  
Aristotle University of Thessaloiki  
Department of Dermatology  
54124 Thessaloniki, Greece

Celeste Lebbé, MD  
Professor of Dermatology  
Department of Dermatology  
Hôpital Saint-Louis  
1, Avenue Claude-Vellefaux  
75010 Paris, France  
Phone: +33-142494679  
Email: celeste.lebbe@aphp.fr

M

Josep Malvehy, MD  
Director of the Melanoma Unit  
Department of Dermatology  
Hospital Clinic of Barcelona  
C/Villarroel 170  
08036 Barcelona, Spain  
Phone: +34-933638920  
Email: jmalvehy@clinic.ub.es

Olivier Michielin, MD  
Head of Melanoma Clinic  
Department of Oncology  
Swiss Institute of Bioinformatics  
Ludwig Institute  
1015 Lausanne  
Switzerland  
Phone: +41-21-692-4053  
Email: Olivier.Michielin@chuv.ch

David Moreno-Ramirez, MD  
University Hospital Virgen Macarena  
Calle Dr. Fedriani, 3  
41009 Seville, Spain
O

**Judit Oláh, MD**  
Department of Dermatology  
University of Szeged  
Koranyi Fasor 6  
3720 Szeged, Hungary  
Phone: +36-62-545984  
Email: dr.olah.judit@gmail.com

P

**Ketty Peris, MD**  
Department of Dermatology  
Catholic University of Rome  
Largo a Gemelli, 8  
00168 Rome, Italy  
Phone: +39-630154227  
Email: ketty.peris@rm.unicatt.it

S

**Dirk Schadendorf, MD**  
University Hospital of Essen  
Hufelandstr. 55  
45147 Essen, Germany  
Phone: +49-201-7232430  
Email: dirk.schadendorf@uk-essen.de

**Alexander Stratigos, MD**  
Department of Dermatology  
University of Athens  
School of Medicine  
Andreas Sygros Hospital  
5 Dragoumi Street  
Athens 161 21, Greece  
Phone: +30-210-7231731  
Email: alstrat2@gmail.com

V

**Ricardo Vieira, MD**  
Faculty of Medicine  
University of Coimbra  
Pólo I - Edífico Central  
Rua Larga  
3004-504 Coimbra, Portugal  
Phone: +35-1-3957-00  
Email: ricardo.vieira@portugalmail.pt

W

**Michael Weichenthal, MD**  
Professor of Dermatology  
Department of Dermatology  
University of Kiel  
Rosalind-Franklin-Str. 7  
24105 Kiel, Germany  
Phone: +49-431-500-21141  
Email:mweichenthal@dermatology.uni-kiel.de

Z

**Iris Zalaudek, MD**  
Head of the Dermatology Clinic  
University of Trieste  
Hospital Maggiore  
Piazza dell’ Ospedale 1  
34125 Trieste, Italy  
Email: iris.zalaudek@gmail.com
Cancellation Policy
Cancellations must be received in writing by December 19, 2019. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

Course Organization

MedConcept Gesellschaft für medizinische Projekte mbH
Friedenstraße 58
15366 Neuenhagen b. Berlin, Germany
Phone: +49 (0)3342 42689-30
Fax: +49 (0)3342 42689-40
E-Mail: info@medconcept.org
www.medconcept.org

Course Venue
ABBA Hotel Berlin
Lietzenburger Str. 89
10719 Berlin
Germany
Phone: +49 (0)30 8871860
E-Mail: berlin@abbahoteles.com
Exhibition Opening Hours
Thursday, January 16: 13:00–18:30
Friday, January 17: 07:30–18:00
Saturday, January 18: 08:00–13:30

Fees
Registration Fee of **380 Euro (incl. VAT)** covers

- Admission to scientific sessions
- Admission to exhibition
- Bag with course documents
- Welcome reception
- Coffee breaks and lunch
- Certificate of attendance

Language and Translation
The official language of the meeting will be English.
Simultaneous translation will not be provided.

Registration/Information Desk
The registration desk is situated at the ground floor of the
ABBA Hotel Berlin next to the reception.

Opening hours
Thursday, January 16: 12:00-19:00
Friday, January 17: 07:30-18:00
Saturday, January 18: 08:00-14:00
GOLD SPONSOR

NOVARTIS

Bristol-Myers Squibb

BRONZE SPONSORS

MERCK

Pfizer

Pierre Fabre

Roche

FURTHER SPONSORS

IMMUNOCORE

MSD

SUN PHARMA
We’re in pursuit of GROUNDBREAKING RESEARCH

Visit the Bristol-Myers Squibb booth to learn more
Notes
**The Art of Protecting Patients.**

More than half of the patients treated in the adjuvant setting with Tafinlar® + Mekinist® remained recurrence-free **after four years.**

---

**Tafinlar®** (dabrafenib) in combination with Mekinist® is indicated for the adjuvant treatment of Stage III melanoma with a BRAF V600 mutation, following complete resection.

Tafinlar® as monotherapy or in combination with Mekinist® is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.1, 2

---

**Nebenwirkungen:**

**Sehr häufig:** Drucktinte, Eisen(II,III)-oxid (E172), Schellack, Propylenglycol.

**Häufig:** Hydroxyethylcellulose, Polyvinylpyrrolidon (PVP), Schmorles Keratose, Hyperhidrose, Pannikulitis, Hautfissuren, Photosensitivität, Schleimhautentzündung, Gesichtsödem.

**Gelegentlich:** Anstieg der AP und CPK im Blut, Anstieg der GGT.

**Selten:** Gastrointestinale Perforation.

**Gelegentlich:** Anstieg der AP und CPK im Blut, Anstieg der GGT.

**Häufigkeit nicht bekannt:** Tiefenvenenthrombose (TVT)/Lungenembolie, TVT/Lungensperre.

**Anstieg der AP und CPK im Blut, Anstieg der GGT.**

---

**Novartis Pharma GmbH, Roonstr. 25, 90429 Nürnberg.**

**Tel.: (0911) 273-0, Fax: (0911) 273-12 653. www.novartis.de**

---

**Protecting the Art of More than half of the patients treated in the adjuvant setting with Tafinlar® + Mekinist® remained recurrence-free **after four years.**

---

**ALSO APPROVED FOR THE ADJUVANT TREATMENT OF MELANOMA.**

For stage-III melanoma with BRAF V600 mutation.
Save the Date
July 9th–10th, 2020
Munich, Germany
Hilton Hotel Munich Park

www.postchicago2020.org

10th European Post-Chicago Melanoma/Skin Cancer Meeting

Congress Presidents
Axel Hauschild, Kiel, Germany
Claus Garbe, Tuebingen, Germany